Cancer immunotherapy in patients with preexisting rheumatologic disease: The Mayo Clinic experience
Arthritis & Rheumatism Jan 29, 2018
Richter MD, et al. - Authors pursued this research in order to gauge the risk of rheumatologic disease flare and adverse effects in patients with preexisting rheumatologic disease receiving checkpoint inhibitor therapy. No substantial variations were brought to light with regard to time from cancer diagnosis to immunotherapy, duration of immunotherapy, age, or sex between the patients with and without Immune-related adverse effects (IRAEs). It was discovered that only a minority of the patients experienced a flare of their preexisting rheumatologic disease or any other IRAE.
Go to Original
Only Doctors with an M3 India account can read this article. Sign up for free or login with your existing account.
4 reasons why Doctors love M3 India
-
Exclusive Write-ups & Webinars by KOLs
-
Daily Quiz by specialty
-
Paid Market Research Surveys
-
Case discussions, News & Journals' summaries